Provided by Tiger Trade Technology Pte. Ltd.

Aclaris Therapeutics

3.52
0.0000
Post-market: 3.520.00000.00%17:50 EDT
Volume:2.39M
Turnover:8.43M
Market Cap:424.50M
PE:-6.64
High:3.61
Open:3.50
Low:3.40
Close:3.52
52wk High:4.89
52wk Low:1.05
Shares:120.60M
Float Shares:116.53M
Volume Ratio:1.06
T/O Rate:2.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5300
EPS(LYR):-0.5300
ROE:-50.20%
ROA:-24.32%
PB:4.12
PE(LYR):-6.64

Loading ...

Aclaris Therapeutics Inc - Phase 2B Program Encompassing Asthma and Atopic Dermatitis Expected to Start in H2 2026

THOMSON REUTERS
·
Feb 24

Aclaris Therapeutics Inc - Top Line Results Expected in Second Half of 2026

THOMSON REUTERS
·
Feb 24

Aclaris Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview

Reuters
·
Feb 23

Aclaris Therapeutics to Present at Major Healthcare Conferences

Reuters
·
Feb 04

Aclaris Therapeutics to Participate in Two February Healthcare Conferences

GlobeNewswire
·
Feb 04

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 28

Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug

Benzinga_recent_news
·
Jan 28

Aclaris Therapeutics reports ‘positive’ results from ATI-2138

TIPRANKS
·
Jan 27

Aclaris Therapeutics Inc - to Initiate Phase 2B Trial for ATI-2138 in First Half of 2026

THOMSON REUTERS
·
Jan 27

Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

GlobeNewswire
·
Jan 27

Aclaris Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since January 2024 -- Data Talk

Dow Jones
·
Jan 27

Aclaris Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 21

Aclaris Therapeutics Up Over 32%, On Track for Largest Percent Increase Since November 2024 -- Data Talk

Dow Jones
·
Jan 21

Aclaris Therapeutics Launches Phase 1b Trial of Bispecific Antibody ATI-052 in Atopic Dermatitis

Reuters
·
Jan 12

Aclaris Therapeutics Initiates Phase 1B Proof-of-Concept Trial in Atopic Dermatitis (Ad) With Its Novel Bispecific Antibody ATI-052

THOMSON REUTERS
·
Jan 12

Aclaris Therapeutics Inc - Top Line Results From Poc Trials Expected in H2 2026

THOMSON REUTERS
·
Jan 12

Aclaris Therapeutics Inc - to Initiate Phase 1B Trial in Asthma This Quarter

THOMSON REUTERS
·
Jan 12

BUZZ-U.S. STOCKS ON THE MOVE-United Airlines Holdings, Energy companies, Tesla

Reuters
·
Jan 07

BUZZ-U.S. STOCKS ON THE MOVE-Shake Shack, Arrowhead Pharmaceuticals, Lockheed Martin

Reuters
·
Jan 06

BUZZ-U.S. STOCKS ON THE MOVE-Alkermes, Ball Corp, NovaBridge

Reuters
·
Jan 06